Boston Scientific (BSX) Total Debt (2009 - 2026)

Boston Scientific has disclosed Total Debt across 18 years of filings, most recently posting $11.0 billion for Q1 2026.

• Total Debt for Q1 2026 came in at $11.0 billion, down 2.48% year-over-year; the trailing twelve-month figure through Mar 2026 was $11.0 billion (down 2.48% YoY), and the FY2025 annual result was $11.4 billion, up 6.42% from the prior year.
• Total Debt came in at $11.0 billion for Q1 2026 at Boston Scientific, down from $11.4 billion in the prior quarter.
• In the past five years, Total Debt ranged from a high of $11.6 billion in Q3 2025 to a low of $8.6 billion in Q3 2022.
• The 5-year median for Total Debt is $10.6 billion (2024), against an average of $10.1 billion.
• Across the five-year window, Total Debt dropped 5.51% in 2022 and climbed 22.32% in 2024, its largest moves.
• Boston Scientific's Total Debt stood at $8.9 billion in 2022, then advanced by 1.87% to $9.1 billion in 2023, then advanced by 18.06% to $10.7 billion in 2024, then climbed by 6.42% to $11.4 billion in 2025, then retreated by 3.56% to $11.0 billion in 2026.
• The last three Total Debt figures came in at $11.0 billion (Q1 2026), $11.4 billion (Q4 2025), and $11.6 billion (Q3 2025), per Business Quant data.